Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 11

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 11
---
 Number of Warrants  
    Weighted Average Exercise Price  
    Weighted Average Remaining Contractual Term (Years)  
    Aggregate Intrinsic Value 
  
    Outstanding as December 31,
    2023 
     1,763,570  
    $3.88  
     4.60  
         - 
  
    Granted 
     -  
    $-  
     -  
     - 
  
    Outstanding as June 30, 2024 
     1,763,570  
    $3.88  
     4.42  
     - 

    Outstanding as December 31, 2024 
     1,763,570  
    $3.88  
     3.60  
     - 
  
    Granted 
     -   
    $-  
     -  
     - 
  
    Outstanding as June 30, 2025 
     1,763,570  
    $3.88  
     2.00  
     - 
  
    Exercisable, June 30, 2025 
     1,763,570  
    $3.88  
     3.42  
     - 

    11

MIRA
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Unaudited)

Note
6. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The Chief Operating Decision Maker for the Company is the CEO. The Company’s CEO reviews operating
results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance
and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The
CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a basis
for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1 herein and in the